Mirum Pharma gains after Evercore raises PT on liver drugs potential

Shares of Mirum Pharmaceuticals MIRM.O rise 2.15% to $89.69

Evercore ISI raises PT to $126 from $101 and reiterates an "outperform" rating

MIRM "checks all the boxes" with its growing rare-liver disease portfolio plus upcoming data from multiple key trials, clear competitive outlooks, and a real margin expansion story, says Evercore analyst Gavin Clark-Gartner

MIRM expects mid-stage data for experimental liver disease drug volixibat and interim late-stage data for hepatitis D drug candidate brelovitug in Q2 2026

Brokerage expects global unadjusted peak sales of $1.2 billion for volixibat in primary sclerosing cholangitis, a rare, chronic, progressive liver disease

MIRM shares rose over 91% in 2025